These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 36683507)

  • 1. The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive Modulators.
    Moebius HJ; Church KJ
    J Alzheimers Dis; 2023; 92(1):1-12. PubMed ID: 36683507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions.
    Abeysinghe AADT; Deshapriya RDUS; Udawatte C
    Life Sci; 2020 Sep; 256():117996. PubMed ID: 32585249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia.
    Johnston JL; Reda SM; Setti SE; Taylor RW; Berthiaume AA; Walker WE; Wu W; Moebius HJ; Church KJ
    Neurotherapeutics; 2023 Mar; 20(2):431-451. PubMed ID: 36538176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of the cerebrospinal fluid hepatocyte growth factor with Alzheimer's disease pathology and cognitive function.
    Zhao LJ; Wang ZT; Ma YH; Zhang W; Dong Q; Yu JT; Tan L;
    BMC Neurol; 2021 Oct; 21(1):387. PubMed ID: 34615471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agmatine as a novel intervention for Alzheimer's disease: Pathological insights and cognitive benefits.
    Katariya RA; Sammeta SS; Kale MB; Kotagale NR; Umekar MJ; Taksande BG
    Ageing Res Rev; 2024 Apr; 96():102269. PubMed ID: 38479477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal loss.
    Ager RR; Davis JL; Agazaryan A; Benavente F; Poon WW; LaFerla FM; Blurton-Jones M
    Hippocampus; 2015 Jul; 25(7):813-26. PubMed ID: 25530343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Alzheimer's disease drug development landscape.
    van Bokhoven P; de Wilde A; Vermunt L; Leferink PS; Heetveld S; Cummings J; Scheltens P; Vijverberg EGB
    Alzheimers Res Ther; 2021 Nov; 13(1):186. PubMed ID: 34763720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
    Suzuki K; Iwata A; Iwatsubo T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs.
    Lozupone M; Solfrizzi V; D'Urso F; Di Gioia I; Sardone R; Dibello V; Stallone R; Liguori A; Ciritella C; Daniele A; Bellomo A; Seripa D; Panza F
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):319-335. PubMed ID: 32772738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current Clinical Trials in the Treatment of Alzheimer's Disease].
    Tamaoka A
    Brain Nerve; 2020 Jan; 72(1):23-34. PubMed ID: 31907330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
    Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
    Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
    Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
    J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
    Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D
    J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.
    Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN
    Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives.
    Imbimbo BP; Lozupone M; Watling M; Panza F
    Expert Opin Investig Drugs; 2020 Sep; 29(9):919-933. PubMed ID: 32657175
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.